Business Wire

Calastone Announces Strategic Partnership With Microsoft to Accelerate the Digital Transformation of Funds and Collective Investments

Share

Calastone, the largest global funds network, has signed a partnership agreement with Microsoft, which will see the firms collaborate on the use of cloud and distributed ledger technology to create market efficiency across the global investment funds industry. By combining Calastone’s network, technology and market experience, with Microsoft’s expertise and track record in delivering capital markets solutions in Microsoft Azure, the companies will drive new opportunities for collective investments worldwide.

Calastone is leveraging its network as the foundation on which to enable the asset management industry to realise its digital transformation agenda. As investor requirements grow for accessible, low cost and innovative ways of investing, Calastone is applying the very latest technologies to build the next generation infrastructure for the distribution of investment funds.

Calastone introduced DMI Fund Services, a suite of solutions that provides fund managers, administrators and distributors a fully digital operating model, enabled through the use of cloud and DLT. In the development of DMI Fund Services, Calastone chose Azure for its reliability, security, scalability and leading-edge confidential computing platform which includes the confidential consortium framework (CCF).

CCF is an open-source framework for building a new category of secure, highly available, and performant applications that focus on multi-party confidential compute and storage. Through Calastone’s practical experience having operated DLT since 2019, the firm has selected CCF as the best framework to provide the rapid scalability and security required to operate on a global scale. This will allow for transformative fund trading and dynamic data sharing across the entire industry, in one common infrastructure.

As DMI Fund Services and Azure confidential computing evolve, the partnership between Calastone and Microsoft will deliver new capabilities, which will enable transfer agents, fund managers and fund distributors to transform how they operate and service their clients, and ultimately gain from the wholescale market efficiency to lower the overall cost of investing.

Adam Belding, Chief Technology Officer at Calastone, said, “The funds industry is at a turning point, with the need to innovate and digitally transform becoming the key goal of asset managers and asset servicers. We absolutely believe that this technology is the future for the funds industry, and for financial services generally. We have great ambitions for DMI Fund Services and our wider product set, and so we looked to Microsoft, one of the world’s leading technology companies, with a proven expertise in enabling distributed ledger and cloud solutions for the financial services sector, to help us drive towards these goals.

“Microsoft’s technologies and industry track record will enable the rapid scaling we see for DMI Fund Services, and our global funds network generally. We are excited to share this vision with Microsoft and look forward to collaborating to revolutionize the funds sector and provide a more efficient and friction-free experience for all.”

Bill Borden, Corporate Vice President of Worldwide Financial Services at Microsoft, said, “We’re excited to work with Calastone to enable innovation in the asset management and capital markets industries. Calastone’s DMI Fund Services, combined with Microsoft Azure and distributed ledger technology, unlocks a secure and scalable way for firms to access the critical data and insights they need to further enhance the client experience, significantly reduce operating costs, and develop new investment models.”

About Calastone

Calastone is the largest global funds network, connecting the world’s leading financial organisations.

Our mission is to help the funds industry transform by creating innovative new ways to automate and digitalise the global investment funds marketplace, reducing frictional costs and lowering operational risk to the benefit of all. Through this, we generate the opportunity for the industry to deliver greater value back to the end investor.

Over 2,800 clients in 51 countries and territories benefit from Calastone’s services, processing £200 billion of investment value each month.

Calastone is headquartered in London and has offices in Luxembourg, Hong Kong, Taipei, Singapore, New York, Milan and Sydney.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

FTI Consulting LLP
Ollie Bailey-Pratt / Darius Alexander
calastone@fticonsulting.com
Tel: 020 3727 1000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye